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A B S T R A C T
This is a protocol for a Cochrane Review (Diagnostic test accuracy). The objectives are as follows:
To determine the diagnostic accuracy of Xpert®MTB/RIF for the detection of extrapulmonary TB by site of disease in people suspected
of having extrapulmonary TB. The role of Xpert® MTB/RIF would be a replacement for standard practice.
To determine the diagnostic accuracy of Xpert® MTB/RIF for detection of rifampicin resistance in people suspected of having
extrapulmonary TB. The role of Xpert® MTB/RIF would be an initial test for replacement for culture-based DST.
We plan to investigate the impact of covariates on heterogeneity in estimates of test accuracy across the included studies.
Detection of extrapulmonary TB
The covariates of interest are: HIV prevalence; condition of the specimen (fresh versus frozen); sample input volume (for liquid
specimens); homogenization step (for tissue specimens); smear status of specimen; past history of TB; and prevalence of extrapulmonary
TB. In addition, we plan to explore whether the WHO standard operating procedures for a given type of specimen were followed
and can explain the observed heterogeneity in accuracy estimates. For TB meningitis we plan to investigate whether the use of a
concentration step prior to the use of Xpert®MTB/RIF has an impact on accuracy estimates. In addition, for detection of lymph node
TB, pleural TB, and TB meningitis, we plan to adjust accuracy estimates by applying a latent class meta-analysis model to account for
the imperfect nature of culture as the reference standard.
Detection of rifampicin resistance detection
The covariate of interest is the prevalence of rifampicin resistance.
1Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
B A C K G R O U N D
Tuberculosis (TB) causes tremendous suffering worldwide and
now ranks aboveHIV/AIDS as the world’s leading infectious cause
of death. TB is caused by infection with Mycobacterium tubercu-
losis (M. tuberculosis) bacteria. The World Health Organization
(WHO) estimates that globally in 2015, 10.4 million people be-
came ill with TB and 1.8 million people died, including 0.4 mil-
lion HIV-positive people (WHO 2016a). In addition, globally in
2015, there were an estimated 480,000 new cases of multidrug-
resistant TB (MDR-TB) and 100,000 cases of rifampicin-resis-
tant TB (WHO 2016a). MDR-TB is caused by infection with
M. tuberculosis bacteria that are resistant to at least rifampicin and
isoniazid, two of the most effective anti-TB drugs. When people
receive proper treatment, TB is treatable and curable.
TB predominantly affects the lungs (pulmonary TB). Extrapul-
monary TB refers to TB in parts of the body other than the lungs,
and is known to affect virtually every part, with lymph nodes and
pleura being the most common sites (Sharma 2004). While active
pulmonary TB is transmissible by droplets spread by coughing in-
dividuals, extrapulmonary TB is thought to result from hematoge-
nous spread from an initial lung infection, and is not infectious.
Extrapulmonary TB can occur alone or together with pulmonary
TB. Of the 6.1million new cases of TB notified toWHO in 2015,
15%were extrapulmonary TB cases (WHO 2016a). However, the
number of people affected by extrapulmonary TB is likely to be
higher, considering that, according toWHO, extrapulmonary TB
is notified as pulmonary TB when the two forms exist together
(WHO 2014b), and diagnosing extrapulmonary TB is challeng-
ing, as described below.Additionally, extrapulmonaryTBaccounts
for an increasing proportion of new TB cases in some countries, in
part due to the increased incidence of extrapulmonary TB associ-
ated with concurrent HIV infection (Golden 2005; Perkins 2007;
Pai 2016). Extrapulmonary TB also affects children in greater pro-
portions than adults (Nelson 2004).
WHO TB treatment guidelines recommend the same drug reg-
imens for extrapulmonary and pulmonary disease with notable
mention of other guidelines which recommend longer treatment
for TB meningitis and for bone and joint TB (WHO 2010). An
updated guideline, published in 2017 provided recommendations
on the use of adjuvant steroids in the treatment of extrapulmonary
TB disease for TB meningitis (strong recommendation, moderate
certainty evidence) and TB pericarditis (conditional recommenda-
tion, very low certainty evidence) (WHO 2017a). TB treatment
guidelines published in 2016 include Index-TB 2016 (India), and
those issued by the American Thoracic Society, the Centers for
Disease Control and Prevention (CDC), and the Infectious Dis-
eases Society of America (Nahid 2016).
Diagnosis of extrapulmonary TB is challenging for several reasons.
Many forms of extrapulmonary TB require invasive diagnostic
sampling, and gathering adequate specimens can pose a risk of
harm to the patient and be costly. Most forms of extrapulmonary
TB are paucibacillary (TB disease caused by a smaller number
of bacteria), making diagnosis by the conventional method of
smear microscopy less sensitive. This problem particularly affects
resource-limited settings, where the more sensitive methods of
mycobacterial culture and histological examination are not widely
available. There are also limitations associated with culture and
histology: culture takes several weeks, requires a highly-equipped
laboratory, and has reduced sensitivity in paucibacillary disease;
histology relies on highly trained operators and characteristic mor-
phology is shared with other diseases. As a result of these difficul-
ties, diagnosis of extrapulmonary TB is oftenmade on the grounds
of clinical suspicion alone, and many people receive the wrong
diagnosis leading to unnecessary TB treatment or poor outcomes
from untreated extrapulmonary TB. The demand for faster, re-
liable diagnostics that are suitable for resource-limited settings is
clear, and has been defined by the research community (Denkinger
2015). In 2014, the World Health Assembly unanimously ap-
proved the End TB Strategy, a 20-year strategy to end the global
TB epidemic. The END TB strategy calls for early diagnosis of
TB including universal drug susceptibility testing (DST) (WHO
END TB 2014).
Xpert® MTB/RIF is an automated polymerase chain reaction
(PCR) test, which accurately detects pulmonary TB and ri-
fampicin resistance when used on sputum specimens (Steingart
2014). The WHO published updated guidance on the use of
Xpert® MTB/RIF in 2013 (WHO 2013). The updated pol-
icy statement expanded recommendations for the use of Xpert®
MTB/RIF for pulmonary TB in adults and added guidance on the
use of the test for childhoodTB and extrapulmonary TB. Drawing
on a systematic review (Denkinger 2014), and using the Grading
of Recommendations Assessment, Development and Evaluation
(GRADE) approach, the WHO issued the following recommen-
dations related to extrapulmonary TB.
• Xpert® MTB/RIF should be used in preference to
conventional microscopy and culture as the initial diagnostic test
for cerebrospinal fluid (CSF) specimens from patients suspected
of having TB meningitis (strong recommendation given the
urgency for rapid diagnosis, very low quality evidence).
• Xpert® MTB/RIF may be used as a replacement test for
usual practice (including conventional microscopy, culture or
histopathology) for testing specific non-respiratory specimens
(lymph nodes and other tissues) from patients suspected of
having extrapulmonary TB (conditional recommendation, very
low quality evidence).
Subsequently, the use of Xpert®MTB/RIF has been incorporated
into the International Standards for TB Care 2014 (TB Care I
2014).
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Currently the manufacturer, Cepheid Incorporated (Sunnyvale,
CA, USA), has made no specific recommendations for the use of
Xpert® MTB/RIF in non-sputum specimens, and accordingly,
Xpert® MTB/RIF is approved by the United States Food and
Drug Administration (FDA) for use in raw sputum specimens and
concentrated sputum sediment only (FDA 2013).
Target condition being diagnosed
Extrapulmonary TB
The various forms of extrapulmonary TB cause signs and symp-
toms related to the structures affected. Table 1 describes the forms
of extrapulmonary TB included in this Cochrane Review, as well
as the different specimens that may be acquired for diagnosis.
Rifampicin resistance
Rifampicin inhibits bacterial DNA-dependent RNA polymerase,
encoded by the RNA polymerase gene (rpoB) (Hartmann 1967).
Resistance to this drug has mainly been associated with mutations
in a limited region of the rpoB gene (Telenti 1993). Rifampicin
resistance may occur alone or in association with resistance to
isoniazid and other drugs. In settings with a high burden ofMDR-
TB, the presence of rifampicin resistance alone may serve as a
proxy for MDR-TB (WHO 2011).
Index test(s)
Xpert® MTB/RIF is a diagnostic test for detection of M. tuber-
culosis complex DNA and, when M. tuberculosis complex is de-
tected, rifampicin resistance-associatedmutations of therpoB gene.
The test results are available within two hours after starting the
test, and with minimal hands-on technical time. Unlike conven-
tional nucleic acid amplification tests (NAATs), Xpert® MTB/
RIF integrates sample processing and PCR amplification and de-
tection into a single self-enclosed test unit, the GeneXpert car-
tridge (Blakemore 2010). Following sample loading, all steps in
the assay are completely automated and self-contained. In addi-
tion, the assay’s sample reagent, used to liquefy sputum, has po-
tent tuberculocidal (the ability to kill TB bacteria) properties and
so largely eliminates biosafety concerns during the test procedure
(Banada 2010). Xpert®MTB/RIF detects both live and dead bac-
teria (Miotto 2012).
Xpert® MTB/RIF uses molecular beacon technology to detect
rifampicin resistance. Molecular beacons are nucleic acid probes
that recognize and report the presence or absence of the normal,
rifampicin-susceptible, ’wild type’ sequence of the rpoB gene of
TB. Five different coloured beacons are used, each covering a sep-
arate nucleic acid sequence within the amplified rpoB gene.
Although Xpert® MTB/RIF provides testing for both M. tuber-
culosis and rifampicin resistance, it is really only one test. One
cannot deselect testing for rifampicin resistance and only run the
assay for TB detection. Xpert®MTB/RIF may be used at all levels
of the health system. However, with the current device, a stable
and uninterrupted electrical supply is required. The WHO has
published extensive guidance and practical information on imple-
menting the test (WHO 2014a).
Since Xpert® MTB/RIF was released, there have been four gen-
erations (G1, G2, G3, and G4) of the cartridge. G4 is the Xpert®
MTB/RIF cartridge in current use and has been in the field for sev-
eral years (Cepheid 2015). The WHO has recently endorsed the
next-generation assay, theXpert®MTB/RIFUltra assay, conclud-
ing that, compared to G4, the Ultra cartridge showed improved
sensitivity for detection of TB, in particular, in populations who
are difficult to diagnose, children, people with extrapulmonary
TB, and people living with HIV (WHO 2017b). To improve de-
tection of M. tuberculosis, Ultra incorporates two different multi-
copy amplification targets (IS6110 and IS1081) and to improve
detection of rifampicin resistance, Ultra usesmelting temperature-
based analysis instead of real-time PCR (WHO 2017b). We will
include studies that use any of the Xpert® MTB/RIF cartridge
generations, as well as the new version, Xpert® MTB/RIF Ultra,
in this Cochrane Review.
Clinical pathway
In this section and Figure 1 we describe the clinical pathway and
present the context in which Xpert® MTB/RIF might be used.
The target condition is extrapulmonary TB, of which there are
several forms (such as pleural TB and TB meningitis). Prior to
testing a specimen with Xpert® MTB/RIF, patients suspected of
having extrapulmonary TB would received a history, physical ex-
amination, and possibly a chest radiograph. The presentation of
extrapulmonary TB varies depending on the body site affected and
may imitate other diseases, such as cancer and bacterial and fungal
infections. The signs and symptoms of extrapulmonary TB are of-
ten non-specific and may include fever, night sweats, fatigue, loss
of appetite, and weight loss (as seen in pulmonary TB) or specific
complaints related to the involved site (for example, headache for
TB meningitis and back pain for TB of the spine). The clinical
presentation of extrapulmonary disease may be acute, but is more
often subacute (falling between acute and chronic) or chronic,
meaning that patients may have symptoms for days to months
before they seek care. Signs and symptoms for the forms of extra-
pulmonary TB included in this review are described in Table 1.
The clinician should take a careful history noting history of TB
exposure, prior TB disease, and medical conditions that increase
the risk for TB disease (such as HIV, diabetes mellitus, and low
body weight). In comparison with HIV-negative people, HIV-
positive people have higher rates of extrapulmonary TB or my-
cobacteraemia (TB bloodstream infection). HIV-positive patients
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with signs or symptoms of extrapulmonary TB should have spec-
imens taken from the suspected site(s) of involvement to increase
the likelihood of TB diagnosis. In general, children with extrapul-
monary TB present in a similar way to that of adults. However,
infants and young children are at the highest risk of developing
disseminated TB disease andTBmeningitis, themost severe forms
of TB. In TB meningitis, diagnosis is often delayed with appalling
consequences for patients. For all forms of extrapulmonary TB,
patients may be evaluated in a primary or secondary care setting.
However, if more complex or invasive tests are needed, patients
may be referred to a tertiary medical centre (Iseman 2000; Sharma
2004; Reuter 2009).
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Figure 1. Abbreviations: DR-TB: drug resistant TB; MDR-TB: multidrug-resistant TB; RIF: rifampicin; SL-
LPA: line probe assay for second-line drugs; TB: tuberculosis; Xpert®: Xpert® MTB/RIF.The Clinical Pathway.
The clinical pathway describes how patients might present and the point in the pathway at which participants
would be considered for testing with Xpert® MTB/RIF. Prior to testing a specimen with Xpert® MTB/RIF,
participants suspected of having extrapulmonary TB would have received a history, physical examination, and
possibly a chest radiograph. The presentation of extrapulmonary TB varies depending on the body site
affected and may imitate other diseases such as cancer and bacterial and fungal infections. The signs and
symptoms of extrapulmonary TB are often non-specific and may include fever, night sweats, fatigue, loss of
appetite, and weight loss (as seen in pulmonary TB) or specific complaints related to the involved site (for
example, headache for TB meningitis and back pain for TB of the spine). The clinical presentation of
extrapulmonary disease may be acute, but is more often subacute (falling between acute and chronic) or
chronic, meaning that patients may have symptoms for days to months before they seek care. Signs and
symptoms for the forms of extrapulmonary TB included in this review are described in Table 1. Standard
practice includes obtaining specimens for microscopy, culture, and histological examination. We adapted this
algorithm for Xpert® MTB/RIF from the Global Laboratory Iniatiative (GLI 2017).
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The purpose of Xpert® MTB/RIF is diagnosis of TB and detec-
tion of rifampicin resistance. The role of Xpert®MTB/RIF is a re-
placement for standard practice, which includes obtaining appro-
priate specimens from the suspected sites of involvement for mi-
crobiological (conventional microscopy and culture) and histolog-
ical examination. An Xpert® MTB/RIF test is recommended as
the preferred initial microbiological test for suspected TB menin-
gitis because of the need for a rapid diagnosis (WHO 2013; TB
Care I 2014). In HIV-positive people with a CD4 cell count less
than or equal to 100 cells/µL, or HIV-positive people who are se-
riously ill regardless of CD4 count, the lateral flow urine lipoarabi-
nomannan assay (LF-LAM) (see ’Alternative test(s)’ section) may
be used to assist in the diagnosis of TB (WHO 2015). TheWHO
further recommends that: “Individuals suspected of having extra-
pulmonary TB but who have had a single negative result from
Xpert®MTB/RIF should undergo further diagnostic testing, and
those for whom there is a high clinical suspicion for TB (especially
children) should be treated even if an Xpert® MTB/RIF result is
negative or if the test is not available” (WHO 2013). The down-
stream consequences of Xpert® MTB/RIF testing are as follows.
• True positives (TP): patients would benefit from rapid
diagnosis and appropriate treatment.
• True negatives (TN): patients would be spared unnecessary
treatment and benefit from reassurance and pursuit of alternative
diagnosis.
• False positives (FP): patients would likely experience
anxiety and morbidity caused by additional testing, unnecessary
treatment, and possible adverse effects; possible stigma associated
with a TB or MDR-TB diagnosis; and the chance that a false
positive may halt further diagnostic evaluation.
• False negatives (FN): an increased risk of morbidity and
mortality, delayed treatment initiation for patients, and the
continued risk of TB transmission in the community.
Alternative test(s)
In this section, we describe alternative tests for detection of ex-
trapulmonary TB and rifampicin resistance. For a comprehensive
review of new tests in the diagnostic pipeline, we refer the reader
to an excellent resource (Unitaid 2017).
It is recommended that clinicians who evaluate patients consid-
ered to have extrapulmonary TB adhere to Standard 4 of the Inter-
national Standards for TB Care, which states: “For all patients, in-
cluding children, suspected of having extrapulmonary TB, appro-
priate specimens from the suspected sites of involvement should
be obtained for microbiological and histological examination. An
Xpert® MTB/RIF test is recommended as the preferred initial
microbiological test for suspected TB meningitis because of the
need for a rapid diagnosis“ (TB Care I 2014).
Smearmicroscopy (that is, lightmicroscopy (Ziehl-Neelsen), fluo-
rescencemicroscopy, or Light-EmittingDiode (LED) fluorescence
microscopy) is the examination of smears for acid-fast bacilli (TB
bacteria) under amicroscope. For extrapulmonaryTB,microscopy
can be performed on fluid or tissue specimens from sites of dis-
ease involvement, for example on CSF in suspected TBmeningitis
or lymph node tissue biopsy in suspected lymph node TB. The
identification of acid-fast bacilli by microscopy in specimens from
most extrapulmonary sites is less frequent (because there are usu-
ally fewer organisms in extrapulmonary sites) and rapid molecular
tests, culture, or both tests are more important (Iseman 2000; TB
Care I 2014).
Histological examination involves the examination of tissue spec-
imens under a microscope. Diagnosis of extrapulmonary TB by
histological examination is based on finding the presence of gran-
ulomatous inflammation with caseous (cheese-like) necrosis and
acid-fast bacilli. The contribution of histology to the diagnosis of
extrapulmonaryTBhas been reported to vary for different forms of
extrapulmonary TB, as well as for different diagnostic techniques.
In patients with TB pleural effusions, granulomatous inflamma-
tion has been reported in 50% to 97% of patients (Gopi 2007),
whereas in patients with lymph node TB, granulomatous inflam-
mation has been reported in 32% to 88% of patients (Fontanilla
2011). Regarding diagnostic techniques, Diacon 2003 found tho-
racoscopy to be more sensitive (sensitivity of 100%) than closed
needle biopsy (sensitivity of 66%) for establishing a diagnosis of
pleural TB. Histological examination carries the additional con-
cern that invasive procedures that are complex and costly may be
required to obtain the necessary specimens (Golden 2005).
NAAT is a molecular technique that can detect small quantities
of genetic material (DNA or RNA) frommicroorganisms, such as
M. tuberculosis. The key advantage of NAATs is that they are rapid
diagnostic tests, potentially providing a result in a few hours. This
is a particularly important feature of the test in life-threatening
forms of extrapulmonary TB, such as TB meningitis. A variety of
molecular amplification methods are available, of which PCR is
the most common. NAATs are available as commercial kits and
in-house tests (based on a protocol developed in a laboratory) and
are used routinely in high-income countries for TB detection. In-
house PCR is widely used in low-income countries because these
tests are less expensive than commercial kits. An older editorial
summarizing three systematic reviews (140 studies) of commercial
and in-house NAATs (other than Xpert® MTB/RIF) for differ-
ent forms of extrapulmonary TB found relatively low sensitivity
and underscored concerns about the cost and feasibility of this
technology in resource-limited areas (Pai 2008). Similarly, a sys-
tematic review found NAATs to have relatively low sensitivity for
extrapulmonary TB, though high specificity (for example, for TB
meningitis and pleural TB), indicating that these tests cannot be
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used reliably to rule out TB (Dinnes 2007).
GenoTypeMTBDRplus (Hain Lifescience, Nehren, Germany), is
a commercial NAAT that belongs to a category of molecular ge-
netic tests called line probe assays. MTBDRplus detects the pres-
ence of mutations associated with drug resistance to isoniazid and
rifampicin (Nathavitharana 2017). The WHO recommends that
MTBDRplus be used for cultured isolates of M. tuberculosis from
both pulmonary and extrapulmonary sites (WHO 2016b).
The LF-LAM (Alere Determine™ TB LAM Ag, Alere Inc,
Waltham, USA) is a commercially available point-of-care test for
active TB (pulmonary and extrapulmonary TB). The test detects
lipoarabinomannan (LAM), a component of the bacterial cell wall,
which is present in some people with active TB. The test is per-
formed by placing urine on one end of a test strip, with results
appearing as a line (that is, a band) on the strip if TB is present.
The test is simple, requires no special equipment, and shows re-
sults in 25 minutes (Shah 2016). A Cochrane Review found LF-
LAM, whether the test is used for diagnosis or screening, has low
sensitivity to detect TB. However, in HIV-positive people with
low CD4 counts who are seriously ill, LF-LAMmay help with the
diagnosis of TB (Shah 2016).
Rationale
Existing diagnostic tests for extrapulmonary TB are not sensi-
tive enough or are invasive and costly. This Cochrane Review
will estimate sensitivity and specificity of Xpert® MTB/RIF for
detection of extrapulmonary TB and rifampicin resistance. We
are aware of six systematic reviews previously published on this
topic: Chang 2012 (seven studies), Denkinger 2014 (18 stud-
ies), Maynard-Smith 2014 (27 studies), Penz 2015 (37 studies),
Sehgal 2016 (24 studies; pleural fluid only), and Li 2017 (26
studies) (Table 2). Chang 2012 performed literature searching up
to 1 October 2011, Denkinger 2014 up to 15 October 2013,
Maynard-Smith 2014 up to 6 November 2013, Penz 2015 up
to 15 August 2014, Sehgal 2016 up to 31 August 2015, and Li
2017 up to 20 June 2015. The reviews found different pooled
accuracy estimates for different forms of extrapulmonary TB and
noted several limitations, including the following: small number
of samples for a given specimen type, incomplete information on
HIV status, concerns about accuracy of the reference standards
used, limited data for assessing the accuracy of Xpert®MTB/RIF
for detection of rifampicin resistance, and considerable differences
in the preparation of specimens for testing. Concerning the latter,
the WHO has prepared standard operating procedures for prepa-
ration of non-respiratory specimens for use with Xpert® MTB/
RIF (WHO 2014a). This Cochrane Review will enable us to up-
date the literature and provide an opportunity to address some of
the noted limitations.
O B J E C T I V E S
To determine the diagnostic accuracy of Xpert®MTB/RIF for the
detection of extrapulmonary TB by site of disease in people sus-
pected of having extrapulmonary TB. The role of Xpert® MTB/
RIF would be a replacement for standard practice.
To determine the diagnostic accuracy of Xpert® MTB/RIF for
detection of rifampicin resistance in people suspected of having
extrapulmonary TB. The role of Xpert® MTB/RIF would be an
initial test for replacement for culture-based DST.
Secondary objectives
We plan to investigate the impact of covariates on heterogeneity
in estimates of test accuracy across the included studies.
Detection of extrapulmonary TB
The covariates of interest are: HIV prevalence; condition of the
specimen (fresh versus frozen); sample input volume (for liquid
specimens); homogenization step (for tissue specimens); smear sta-
tus of specimen; past history of TB; and prevalence of extrapul-
monary TB. In addition, we plan to explore whether the WHO
standard operating procedures for a given type of specimen were
followed and can explain the observed heterogeneity in accuracy
estimates. For TB meningitis we plan to investigate whether the
use of a concentration step prior to the use of Xpert® MTB/RIF
has an impact on accuracy estimates. In addition, for detection
of lymph node TB, pleural TB, and TB meningitis, we plan to
adjust accuracy estimates by applying a latent class meta-analysis
model to account for the imperfect nature of culture as the refer-
ence standard.
Detection of rifampicin resistance detection
The covariate of interest is the prevalence of rifampicin resistance.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include primary studies that compare the results of the
index test with the reference standard.Wewill include randomized
controlled trials, cross-sectional studies, and observational cohort
studies.Wewill include studies that report data fromwhichwe can
extract TP, FP, FN, and TN. We will exclude case-control studies.
In addition, we will exclude data reported only in abstracts from
conference proceedings and case reports.
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Participants
For both review questions, we will include participants of all ages
thought to have extrapulmonary TB from all settings and coun-
tries. We will include all patients providing non-respiratory speci-
mens (may include blood, urine, pericardial fluid, ascitic fluid, or
bone biopsy tissue, for example), except as noted. We will exclude
sputum and other respiratory specimens, such as fluid obtained
from bronchial alveolar lavage and tracheal aspiration. Studies will
need to provide data for at least five specimens.We have added this
criterion because we are aware that some studies may include data
for only a few non-respiratory specimens, which we feel would
contribute relatively little in relation to the additional resources
required. We will exclude studies that evaluate Xpert®MTB/RIF
by aspiration of gastric fluid, as this specimen is used mostly for
investigating pulmonary TB in children.Wewill also exclude stool
specimens because TB bacteria may be swallowed and passed into
stool as a marker of pulmonary TB. We will exclude studies eval-
uating the use of Xpert® MTB/RIF to diagnose relapse of previ-
ously treated extrapulmonary TB so as to avoid the selection bias
that may arise by limiting to a group that is already at elevated
risk of extrapulmonary TB. Our intent is to identify studies that
include patients with diagnostic uncertainty who are not taking
anti-TB drugs or who have taken anti-TB drugs for less than seven
days. However, if we find that some studies do include some pa-
tients on TB drugs, we will address this concern in a sensitivity
analysis.
Index tests
The index test is Xpert® MTB/RIF. The index test results are
automatically generated and the user is provided with a printable
test result as follows.
• MTB (M. tuberculosis) DETECTED; Rif (rifampicin)
resistance DETECTED.
• MTB DETECTED; Rif resistance NOT DETECTED.
• MTB detected; Rif resistance INDETERMINATE.
• MTB NOT DETECTED.
• INVALID (The presence or absence of MTB cannot be
determined).
• ERROR (The presence or absence of MTB cannot be
determined).
• NO RESULT (The presence or absence of MTB cannot be
determined).
Non-interpretable results for detection of MTB are classified as
’invalid’, ’error’, or ’no result’. Non-interpretable results for detec-
tion of rifampicin resistance are classified as rifampicin resistance
’indeterminate’.
Target conditions
The target condition is extrapulmonary TB, stratified by site of
disease. We will consider the subcategories of the target condition
as separate diagnostic classifications. We will include the most
common forms of extrapulmonary TB (Sharma 2004; Sandgren
2013; CDC 2014). Table 1 lists forms of extrapulmonary TB and
the specimens suggested for diagnostic testing.
• Lymph node TB.
• Pleural TB.
• TB meningitis.
• Bone and joint TB.
• Genitourinary TB.
• Peritoneal TB.
• Pericardial TB.
• Disseminated TB.
We anticipate that we will find very few studies that evaluate
Xpert®MTB/RIF for bone and joint TB, genitourinary TB, peri-
toneal TB, pericardial TB, and disseminated TB. If so, we will
describe these studies in an appendix and will focus the review
on three subcategories of the target condition: lymph node TB,
pleural TB, and TB meningitis.
Reference standards
Detection of all forms of extrapulmonary TB
The primary reference standard will be solid or liquid mycobacte-
rial culture.
• ’TB’ is defined as a positive M. tuberculosis culture.
• ’Not TB’ is defined as a negative M. tuberculosis culture.
For detection of pleural TB by biopsy of pleural tissue, we will also
include a composite reference standard defined as ’culture or gran-
ulomatous inflammation on histopathological examination, either
test positive’. There is evidence to support including histopatho-
logical examination in the composite reference standard for pleural
TB. Around 60% of patients undergoing pleural biopsy will show
granulomatous inflammation (American Thoracic Society 2000).
In a prospective cohort study of patients with clinical and radi-
ological findings consistent with pleural TB, Conde 2003 found
histological examination of tissue obtained from pleural biopsy to
have a higher diagnostic yield, 78% (66/84), than that of culture
(62% 52/84). For other forms of TB, we decided against the use
of a composite reference standard due to the differing definitions
of the composite reference standards, the difficulty in interpreting
them, and the concern for bias (Schiller 2016).
Culture is considered the best reference standard for TB. However,
culture may misclassify cases of extrapulmonary TB as not TB
due to the paucibacillary nature of the disease. This means that
index test TPs may be misclassified as FPs by culture. Therefore,
when evaluating Xpert® MTB/RIF against culture, the number
of FPs (classified as positive by the index test and negative by the
reference test) may be increased and Xpert®MTB/RIF specificity
may be underestimated. Another drawback of using culture as a
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reference standard is that it amounts to ignoring the dependence
that arises between culture and Xpert® MTB/RIF among true
extrapulmonary TB cases due to their common dependence on
the bacterial load. Both culture and Xpert® MTB/RIF are likely
to pick up cases with a higher bacterial load, and both are likely to
miss cases with a lower bacterial load. Ignoring this dependence
could lead to an overestimation of the sensitivity of Xpert®MTB/
RIF. To improve the estimation of diagnostic accuracy, we plan
to apply latent class analysis to the three most commonly studied
forms of extrapulmonary TB on which we believe it is possible to
gather the data necessary to make the adjustment. We discuss this
approach further in the Statistical analysis and data synthesis’
section.
Detection of rifampicin resistance
The reference standard will be culture-based DST using solid or
liquid media or MTBDRplus as recommended by the WHO (
WHO 2012; WHO 2016b).
Search methods for identification of studies
We will attempt to identify all relevant studies regardless of lan-
guage or publication status (published, unpublished, in press, and
ongoing).
Electronic searches
Vittoria Lutje (VL), the Information Specialist for the Cochrane
Infectious Diseases Group (CIDG), will perform literature
searches without language restrictions. To identify all relevant
studies, VL will search the following databases using the search
terms and strategy described in Appendix 1: CIDG Special-
ized Register; MEDLINE (OVID); Embase (OVID); Science
Citation Index Expanded (SCI-EXPANDED), Conference Pro-
ceedings Citation Index-Science, (CPCI-S), and BIOSIS Pre-
views; all three from Web of Science; LILACS (BIREME; http://
lilacs.bvsalud.org/en/); and Scopus® (Elsevier). VLwill also search
the ISRCTN registry (http://isrctn.com) and the search portal
of the WHO International Clinical Trials Registry Platform (IC-
TRP; http://apps.who.int/trialsearch/) to identify ongoing trials,
and ProQuest Dissertations & Theses A&I to identify relevant
dissertations.
Searching other resources
We will review reference lists of included articles and any relevant
review articles identified through the above methods.We will con-
tact the test manufacturer (Cepheid Inc.) to identify unpublished
studies. We will also handsearch WHO reports on Xpert®MTB/
RIF. We will contact researchers at FIND, members of the Stop
TB Partnership’s New Diagnostics Working Group, and other ex-
perts in the field of TB diagnostics for information on ongoing or
unpublished studies.
Data collection and analysis
Selection of studies
Two review authors will independently scrutinize titles and ab-
stracts identified by electronic literature searching to identify po-
tentially eligible studies. We will select any citation identified by
either review author as potentially eligible for full-text review. Two
review authors will then independently assess the full-text papers
for study eligibility using the predefined inclusion and exclusion
criteria. The review authors will resolve any discrepancies by dis-
cussion, or if they are unable to resolve, by decision of a third
review author. We will list all studies excluded after full-text as-
sessment and their reasons for exclusion in a ’Characteristics of ex-
cluded studies’ table. We will illustrate the study selection process
in a PRISMA diagram.
Data extraction and management
Two review authors will extract a set of data from five studies using
a piloted data extraction form (Appendix 3). Based on the pilot, we
will finalize the extraction form.Next, two review authors working
independently will extract data on the following characteristics.
• Author; publication year; country; setting (outpatient,
inpatient, or both outpatient and inpatient); study design;
manner of participant selection; number of participants enrolled;
number of participants for whom results are available.
• Characteristics of participants: % female; age; % HIV-
positive; % with history of TB.
• Index test version.
• Target condition and subcategories.
• Reference standard.
• QUADAS-2 items.
• Details of specimen: type (such as CSF, pleural fluid, lymph
node aspirate or tissue); condition (fresh or frozen); smear
positive or negative.
• Specimen preparation; homogenization step (for tissue
specimens); concentration step; sample input volume; adherence
to WHO standard operating procedures.
• Number of TP, FP, FN, and TN; the number of non-
interpretable results; the number of indeterminate rifampicin-
resistant results.
• Number of missing or unavailable test results.
When possible, we will extract data for subgroups by HIV status.
We will classify country income status as either low- and mid-
dle-income or high-income, according to the World Bank List of
Economies (World Bank 2017).
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We will extract TP, FP, FN, and TN values for non-respiratory
specimens: pleural, CSF, joint aspirate, urine, peritoneal, pericar-
dial, blood, and biopsy specimens such as lymph node and pleural
tissue, corresponding to the forms of extrapulmonary TB in the
review. In situations where a participant contributes more than
one specimen, but of a different type, we will extract data for all
specimens. When a study includes data for both raw specimens
and concentrated sediment involving the same participants, we
will preferentially extract data for raw specimens, except in the
case of CSF where we will extract data for concentrated sediment
as recommended by the WHO (WHO 2014a). We will only ex-
tract accuracy data for the participants who received the defined
reference standard (see Reference standards). In situations where
a subset of participants in a study received the reference standard
but others did not, we will only extract information on the subset
together with information on the percentage of patients who re-
ceived the reference standard. This will allow us to make correc-
tions for verification bias in the statistical analysis (Begg 1983).
We will contact authors of primary studies for missing data or
clarifications. We will enter all data into a database manager, Mi-
crosoft Excel 2014.
Assessment of methodological quality
We will use the Quality Assessment of Diagnostic Accuracy Stud-
ies (QUADAS-2) tool to assess the quality of the included studies
(Whiting 2011). QUADAS-2 consists of four domains: patient
selection, index test, reference standard, and flow and timing. We
will assess all domains for the potential for risk of bias and the
first three domains for concerns regarding applicability. As recom-
mended, we will first develop guidance on how to appraise each
question and interpret this information tailored to this review.
Then, one review author will pilot the tool with two of the in-
cluded studies. Based on experience gained from the pilot, we will
finalize the tool. Two review authors will independently complete
QUADAS-2.We will resolve disagreements through discussion or
by consulting a third review author. We will present the results of
the quality assessment in the text, table, and graphs.
We will follow Cochrane policy which states that ”authors of pri-
mary studies will not extract data from their own study or studies.
Instead, another author will extract these data, and check the in-
terpretation against the study report and any available study reg-
istration details or protocol”.
Statistical analysis and data synthesis
We will perform descriptive analyses of the characteristics of the
included studies using Stata 12 (Stata 2011), and will present key
study characteristics in the ’Characteristics of included studies’ ta-
ble.We will use data reported in the TP, FP, FN, and TN format to
calculate sensitivity and specificity estimates and 95% confidence
intervals (CI) for individual studies. We will present individual
study results graphically by plotting the estimates of sensitivity and
specificity (and their 95% CIs) in forest plots and receiver operat-
ing characteristic (ROC) space using Review Manager 5 (RevMan
5) (RevMan 2014).
When possible, we will perform meta-analyses to estimate the
pooled sensitivity and specificity and corresponding 95% credi-
ble (Crl, defined below) and prediction intervals using an adapta-
tion of the bivariate random-effects approach of Reitsma (Reitsma
2005; Chu 2009). The bivariate random-effects approach will al-
low us to calculate the pooled estimates of sensitivity and speci-
ficity while dealing with potential sources of variation caused by:
(1) imprecision of sensitivity and specificity estimates within in-
dividual studies; (2) correlation between sensitivity and specificity
across studies; and (3) variation in sensitivity and specificity be-
tween studies.
We will use the following approach. We will perform separate
analyses grouped by type of non-respiratory specimen (for exam-
ple pleural, CSF, or peritoneal), rather than determine summary
accuracy estimates for all forms of extrapulmonary TB combined,
because we think the former approach is most clinically meaning-
ful.
For the analysis of Xpert® MTB/RIF accuracy for rifampicin re-
sistance detection, we will include patients who are (1) culture-
positive; (2) have a valid phenotypic DST (or MTBDRplus) re-
sult; are (3) Xpert® MTB/RIF TB-positive; and have (4) a valid
Xpert® RIF-result.
Sensitivity = Xpert® MTB/RIF RIF-resistant/DST RIF-resistant
Specificity = Xpert® MTB/RIF RIF-susceptible/DST RIF-sus-
ceptible
Culture negative-Xpert® positive-rifampicin resistant positive re-
sults have rarely been described in the literature (Boyles 2014;
Kelly 2014). When reported in the included studies, we will ex-
tract these data and describe them narratively in the ’Findings’ and
’Strengths and weaknesses’ sections of the review.
For our primary analysis and examination of heterogeneity, we
will estimate all models using a Bayesian approach with low-in-
formation prior distributions and implement the models using
WinBUGS (Version 1.4.3) (Lunn 2000). Under the Bayesian ap-
proach, all unknownparametersmust be provided a prior distribu-
tion that defines the range of possible values of the parameter and
the weight of each of those values, based on information external
to the data. In order to let the observed data dominate the final
results, we will choose to use low-information prior distributions.
We will define prior distributions on the log-odds scale over the
pooled sensitivity and specificity parameters, their corresponding
between-study standard deviations and the correlation between
the sensitivities and specificities across studies (see Steingart 2014
and Shah 2016). We will summarize the meta-analysis models
used and corresponding WinBUGS programs in an appendix. It
is known that meta-analysis models can be sensitive to the choice
of prior distributions over the between-study standard deviation
parameters. Therefore, we will carry out sensitivity analyses con-
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sidering alternative prior distributions that are less informative,
allowing a wider range of possible values.
We will combine information from the prior distribution with the
likelihood of the observed data, in accordance with Bayes’ the-
orem using the WinBUGS program, which will provide a sam-
ple from the posterior distribution of each unknown parameter.
We are particularly interested in the pooled sensitivity and speci-
ficity of Xpert® and the between-study variance in the sensitivity
and specificity of Xpert® on the log-odds scale. Using a sample
from the posterior distribution, we will calculate various descrip-
tive statistics of interest. We will estimate the median pooled sen-
sitivity and specificity and their 95% CrI. The median or the 50%
quantile is the value below which 50% of the posterior sample lies.
We will report the median because the posterior distributions of
some parameters may be skewed and themedian would be consid-
ered a better point estimate of the unknown parameter than the
mean in such cases. The 95% CrI is the Bayesian equivalent of the
classical (frequentist) 95% CI (we will indicate 95% CI for indi-
vidual study estimates and 95% CrI for pooled study estimates as
appropriate). The 95% CrI may be interpreted as an interval that
has a 95% probability of capturing the true value of the unknown
parameter given the observed data and the prior information.
We will also determine the predicted sensitivity and specificity of
Xpert® and their 95% CrIs. The predicted values are our best
guess for the sensitivity and specificity in a future study. They
will be close to the pooled estimates. However, their CrIs may
be different. If there is no heterogeneity at all between studies,
the CrI around the predicted estimate will be the same as the
CrI around the pooled estimate. On the other hand, if there is
considerable heterogeneity between studies, the CrI around the
predicted estimate will be much wider than the CI around the
pooled estimate. This will be reflected in a much wider prediction
region compared to the credible region on a bivariatemeta-analysis
plot.
In addition, in a secondary analysis for three forms of extrapul-
monary TB (pleural TB, lymph node TB, and TBmeningitis), we
plan to adjust accuracy estimates by applying a latent class meta-
analysis model to account for the imperfect nature of culture as
the reference standard (Dendukuri 2012).
Latent class analysis is a statistical modelling technique that al-
lows unbiased estimation of test accuracy in the absence of an ad-
equate reference standard to define the presence or absence of dis-
ease (Van Smeden 2014). This model will expand the traditional
model in two ways: (1) we will add parameters for the sensitiv-
ity and specificity of culture; and (2) we will add a conditional
dependence term to adjust for the dependence between Xpert®
MTB/RIF and culture among disease positive participants. Each
study will contribute a 2 x 2 table to this model or three degrees of
freedom. However, there are six unknown parameters at the study
level: sensitivity and specificity of Xpert® MTB/RIF and culture,
prevalence of extrapulmonary TB and the covariance between the
two tests among extrapulmonary TB positive patients. The excess
of three unknown parameters over the number of degrees of free-
dom will render the model non-identifiable. Therefore, we will
have to use an informative prior distribution over at least three
parameters. The covariance term is bounded by the values of the
sensitivities of the two tests. In addition, we plan to use informative
prior distributions over the sensitivity and specificity of culture,
obtained from latent class analyses of large cohort studies where
data are available at the patient level and on more than two tests.
For the analyses where we have an informative prior distribution
for the sensitivity and specificity of culture, we will prepare plots
of the prior and posterior density functions of the different pa-
rameters of interest in order to visually display the impact of the
prior information on the posterior distribution.
Based on recent work evaluating Xpert®MTB/RIF for childhood
TB (Schumacher 2016), we anticipate that these adjustments will
lead to a lowering of the estimated pooled sensitivity of Xpert®
MTB/RIF and an increase in the estimated pooled specificity of
Xpert® MTB/RIF compared to the primary analyses.
Approach to non-interpretable index test results
For detection of extrapulmonary TB, we will define non-inter-
pretable (invalid, error, no result) index results as a third category.
If we find very few non-interpretable results reported, we will ex-
clude non-interpretable results from the quantitative analysis and
analyse them descriptively. Similarly, for detection of rifampicin
resistance, we will define indeterminate index results as a third
category. If we find very few non-interpretable results reported,
we will exclude indeterminate results from the quantitative analy-
sis and analyse them descriptively. In the Discussion section’ of
the review, we will discuss the consequences of an indeterminate
index test result considered to be a false negative result (may lead
to missed or delayed diagnosis, with potential for increased mor-
bidity, mortality, and TB transmission), or considered to be false
positive result (may lead to unnecessary treatment with adverse
effects and increased anxiety).
Investigations of heterogeneity
Initially, we will investigate heterogeneity through visual exami-
nation of forest plots of sensitivities and specificities and through
visual examination of the ROC space of the raw data. If there
are sufficient studies, we will assess heterogeneity through sub-
group analyses or regression modelling. We include the prevalence
of extrapulmonary TB as a covariate because changes in disease
prevalence have often found to be associated with other, impor-
tant changes such as changes in the disease spectrum, which may
affect diagnostic accuracy estimates (Leeflang 2009). All covariates
added to the model will be study level and categorical.
• Smear status (positive or negative).
• Percent HIV-positive individuals (> 10% or ≤ 10%).
• Past history of TB (> 30% or ≤ 30%).
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• Condition of specimen (fresh or frozen).
• Sample input volume for body fluid specimens (> 2 mL or
≤ 2 mL).
• Homogenization step for tissue specimens (yes or no).
• WHO standard procedures for preparing specimen
followed (yes or no).
• Prevalence of extrapulmonary TB (> 20% or ≤ 20%).
• Prevalence of rifampicin resistance (> 5% or ≤ 5%).
• For TB meningitis, concentration step used for preparing
specimen (yes or no).
Sensitivity analyses
If there are sufficient data, we will perform sensitivity analyses to
explore the contribution of risk of bias and patient characteristics
on Xpert®MTB/RIF accuracy by limiting inclusion in the meta-
analysis to the following.
• Studies that used consecutive or random selection of
participants.
• Studies where the reference standard results were
interpreted without knowledge of the index test results.
• Studies that included only untreated patients.
Assessment of reporting bias
We will not perform a formal assessment of publication bias using
methods such as funnel plots or regression tests because such tech-
niques have not been helpful for diagnostic test accuracy studies
(Macaskill 2010).
Assessment of the certainty of the evidence
Two review authors (MK and KRS) will assess the certainty of
the evidence (also called quality of the evidence) using the Grad-
ing of Recommendations Assessment, Development and Evalu-
ation (GRADE) approach (Schünemann 2008; Balshem 2011;
GRADE 2013), and GRADEpro Guideline Development Tool
(GDT) software (GRADEproGDT 2015). In the context of a sys-
tematic review, the ratings of the certainty of the evidence reflect
the extent of our confidence that the estimates of the effect (includ-
ing test accuracy and associations) are correct. As recommended,
we will rate the certainty of the evidence as either high (not down-
graded), moderate (downgraded by one level), low (downgraded
by two levels), or very low (downgraded by more than two levels)
for five domains: risk of bias, indirectness, inconsistency, impre-
cision, and publication bias. For each outcome, we will consider
the certainty of the evidence to begin as high when there are high
quality observational studies (cross-sectional or cohort studies)
that enrolled participants with diagnostic uncertainty. If we find a
reason for downgrading, we will use our judgment to classify the
reason as either serious (downgrade by one level) or very serious
(downgrade by two levels). We will summarize this information
in the ’Summary of findings’ tables (Schünemann 2011).
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A D D I T I O N A L T A B L E S
Table 1. Forms of extrapulmonary TB
Form of extrapulmonary TB Characteristics Diagnostic specimens and means of col-
lection
Lymph node TB, also called TB lym-
phadenitis
MTB infection of lymph nodes. May affect
one node or a group of nodes, or multi-
ple groups within a chain. Lymph node TB
is relatively more common among children
than adults. The most common presenta-
tion is of a single, firm, non-tender enlarged
node in the neck, although any lymph node
group can be affected. This may be ac-
companied by fever, weight loss, and night
sweats, particularly in people withHIV. Pa-
tientswithTB indeep lymphnodes, such as
themediastinal ormesenteric lymphnodes,
may present with fever, night sweats, and
weight loss, or more rarely with symptoms
related to compression of adjacent struc-
tures. Over time lymph nodes become fluc-
tuant and may discharge via a sinus to the
skin or an adjacent viscus. It should be
noted that lymphadenopathy may also be
seen in other forms of TB as part of the
immune response, but this is not usually
caused by direct infection of the lymph
nodes
Fine needle aspirate from affected lymph
node, with or without radiological guid-
ance; excisional biopsy of superficial lymph
nodes; endoscopic biopsy of deep lymph
nodes with ultrasound guidance
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Table 1. Forms of extrapulmonary TB (Continued)
Pleural TB, also called TB pleurisy MTB infection of the pleura presents with
the gradual onset of pleuritic chest pain,
shortness of breath, fever, night sweats, and
weight loss. Chest X-ray may demonstrate
unilateral or occasionally bilateral pleu-
ral effusion. The severity of symptoms is
highly variable, with many patients expe-
riencing spontaneous resolution of symp-
toms,while othersmay develop severe pleu-
ral effusions requiring drainage. Pleuro-
pulmonary TB, where there is parenchy-
mal lung involvement visible on a chest X-
ray, is associated with highermortality than
isolated pleural infection, which appears to
be rarely fatal (Shu 2011).
Pleural aspirate; pleural biopsy, which may
be performed via thoracoscopy or percu-
taneously with an Abram’s needle, with or
without ultrasound guidance
TB meningitis, also called tuberculous
meningitis
MTB infectionof themeninges affects peo-
ple of all ages, but is most common in chil-
dren and people with untreated HIV infec-
tion. In adults, TBmeningitis presentswith
the gradual onset of headache, neck stiff-
ness, malaise, fever, and, if untreated, can
progress to altered sensorium, focal neu-
rological deficits, coma, and death. Young
children may present with poor weight
gain, low-grade fever, and listlessness. In-
fants, may present with fever, cough (re-
lated to the primary pulmonary infection
which occurs before TB meningitis devel-
ops), change of consciousness at presenta-
tion, bulging anterior fontanel, and seizures
(Thwaites 2013). TB meningitis is some-
times associated with a concurrent cerebral
tuberculoma, or more rarely a tuberculous
abscess
CSF, acquired by lumbar puncture with
or without radiological guidance; biopsy of
tuberculoma, acquired surgically
Bone and joint TB MTB infection of the bones or joints or
both causes chronic pain, deformity and
disability, and TB of the cervical spine can
be life-threatening. The usual presenting
symptom is pain. Fever and weight loss,
with or without signs of spinal cord com-
pression, may be present. Patients with ad-
vanced disease may have severe pain, spinal
deformity, paraspinal muscle wasting, and
neurological deficit. Children may have
failure to thrive and difficulty walking
Aspiration of joint fluid or periarticular ab-
scesses; percutaneous computed tomogra-
phy guided biopsy of lesions is preferred,
but some patients may require open biopsy
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Table 1. Forms of extrapulmonary TB (Continued)
Genitourinary TB MTB infection of the genitourinary tract.
Renal TB presents with flank pain, haema-
turia, and dysuria. Female genital TB
presents with infertility (and may be other-
wise asymptomatic), pelvic pain, and vagi-
nal bleeding. Testicular TB presents with a
scrotal mass and infertility
Urine; biopsy of affected organs, acquired
under radiological guidance or surgically
Pericardial TB, also called TB pericarditis MTB infection of the pericardium presents
with fever, malaise, night sweats, and
weight loss. Chest pain and shortness
of breath are also commonly experienced
symptoms. Pericardial TB may be associ-
ated with pericardial effusion, which can
be severe and lead to tamponade, which
is life-threatening. Some patients go on to
develop pericardial constriction, which can
lead to heart failure and death, and may re-
quire surgical intervention even after my-
cobacterial cure
Pericardial fluid acquired by pericardiocen-
tesis;
pericardial biopsy, acquired under radio-
logical guidance or surgically
Peritoneal TB MTB infection of the peritoneum. Peri-
toneal TB usually presents with pain and
abdominal swelling, which may be accom-
panied by fever, weight loss, and anorexia
Ascitic fluid acquired by paracentesis; peri-
toneal biopsy (Chow 2002)
DisseminatedTB, also calledmiliary TB. It
has beenproposed that the designationmil-
iary TB be restricted to disseminated TB
with miliary shadows on chest radiograph
(Reuter 2009)
Disseminated TB refers to TB that involves
two or more distinctly separate sties. Man-
ifestations may be quite varied, ranging
from acute fulminant disease to non-spe-
cific symptoms of fever, weight loss, and
weakness. HIV-positive people are more
likely to have disseminated TB than HIV-
negative people. In a systematic review of
the prevalence of TB in post-mortem eval-
uations of HIV-positive people, in adults
disseminated TB was found in 87.9% (82.
2% to 93.7%) of TB cases and considered
the cause of death in 91.4% (95% CI 85.
8% to 97.0%) of TB cases (Gupta 2015).
Blood; specimens acquired from affected
extrapulmonary sites
Abbreviations: CSF: cerebrospinal fluid; HIV: human immunodeficiency virus; MTB: Mycobacterium tuberculosis; TB: tuberculosis.
We adapted the table from Index-TB 2016.
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Table 2. Systematic reviews of Xpert® MTB/RIF for extrapulmonary TB
Systematic re-
view
Search period Number
of studies (total
number of ex-
trapulmonary
specimens)
Forms of extra-
pulmonary TB
or specimens
Accuracy against culture reference standard
Lymph node
TB
Pleural TB
(pleural fluid)
TB meningitis
Chang 2012 1 Up to 1 October
2011
7 (1058) Multiple forms
combined
Not reported Not reported Not reported
Denkinger 2014 Up to 15
October 2013
18 (4461) Lymph node,
pleural fluid,
CSF
Sensitivity 83%;
specificity 94%
Sensitivity 46%;
specificity 99%
Sensitivity 81%;
specificity 98%
Maynard-Smith
2014
Up to 6 Novem-
ber 2013
27 (6026) Lymph node,
pleural
fluid, CSF, other
forms
Sensitivity 96%;
specificity 93%
Sensitivity 34%;
specificity 98%
Median sensitiv-
ity 85% (IQR
75% to 100%);
median
specificity 100%
(IQR 98% to
100%)
Penz 2015 Up to 15 August
2014
36 (9523) Lymph node,
pleural
fluid, CSF, other
forms
Sensitivity 87%;
specificity 92%
Sensitivity 37%;
specificity 98%
Sensitivity 69%;
specificity 97%
Sehgal 2016 Up to 31 August
2015
24 (2486) Pleural fluid Not applicable Sensitivity 51%;
specificity 99%
Not applicable
Li 2017 2 Up to 20 June
2015
26 (Not
reported)
Multiple forms
combined
Not reported Not reported Not reported
Abbreviations: CI: confidence interval; CSF: cerebrospinal fluid: IQR: interquartile range; TB: tuberculosis.
1For all forms of extrapulmonary TB combined, Chang 2012 reported pooled sensitivity and specificity of 80.4% (95% confidence
interval (CI) 75.0% to 85.1%) and 86.1% (95% CI 83.5% to 88.4%), respectively.
2For both pulmonary and extrapulmonary TB, the authors included 106 studies involving 52,410 samples. For all forms of extrapul-
monary TB combined, Li 2017 reported pooled sensitivity and specificity of 80% (95% CI 69% to 88%) and 97% (95% CI 94% to
98%), respectively.
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A P P E N D I C E S
Appendix 1. Search strategy
1 Mycobacterium tuberculosis/
2 Tuberculosis/ or “Tuberculosis, Multidrug-Resistant”/ or Extensively Drug-Resistant Tuberculosis/
3 (Tuberculosis or MDR-TB or XDR-TB or “Multidrug Resistant Tuberculosis” or “Extensively Drug Resistant Tuberculosis” or
tuberculous).ti. ab .
4 (extrapulmonary or extra-pulmonary or EPTB).ti. ab .
5 (lymphadenitis or disseminated or miliary or pleur* or skeletal or spine or mening* or intracranial or intra-ocular or ocular or
abdominal or splenic or genitourinary or pericardial).ti. ab .
6 “Tuberculosis, Central Nervous System”/ or “Tuberculosis, Urogenital”/ or “Tuberculosis, Splenic”/ or “Tuberculosis, Spinal”/ or
“Tuberculosis, Renal”/ or “Tuberculosis, Pleural”/ or “Tuberculosis, Osteoarticular”/ or “Tuberculosis, Oral”/ or “Tuberculosis, Oc-
ular”/ or “Tuberculosis, Meningeal”/ or “Tuberculosis, Lymph Node”/ or “Tuberculosis, Laryngeal”/ or “Tuberculosis, Hepatic”/ or
“Tuberculosis, Gastrointestinal”/ or “Tuberculosis, Female Genital”/ or “Tuberculosis, Endocrine”/ or “Tuberculosis, Cutaneous”/ or
“Tuberculosis, Cardiovascular”/ or Tuberculosis, Miliary/ or Tuberculosis, Male Genital/
7 1 or 2 or 3
8 4 or 5
9 7 and 8
10 9 or 6
11 Xpert*.ti. ab .
12 (GeneXpert or cepheid).ti.ab .
13 (near* patient or near-patient).ti.ab
14 11 or 12 or 13
15 10 and 14
This is the preliminary search strategy for MEDLINE (OVID). It will be adapted for other electronic databases. We will report all
search strategies in full in the final version of the review.
Appendix 2. Rules for QUADAS-2
Domain 1: Patient selection
Risk of bias: Could the selection of patients have introduced bias?
Signalling question 1: Was a consecutive or random sample of patients enrolled?
We will score “yes” if the study enrolled a consecutive or random sample of eligible patients, “no” if the study selected patients by
convenience, and “unclear” if the study did not report the manner of patient selection or we cannot tell.
Signalling question 2: Was a case-control design avoided?
We will not include studies using a case-control design in the review because this study design, especially when used to compare results
in severely ill patients with those in relatively healthy individuals, may lead to overestimation of accuracy in diagnostic studies. We will
score “yes” for all studies.
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Signalling question 3: Did the study avoid inappropriate exclusions?
We will score “yes” if the study included specimens regardless of prior testing and appearance. We will judge “no” if the study excluded
specimens based on the results of prior testing, appearance of the specimen (for example, purulence), other biochemical analysis (for
example, ADA, cell analysis) or smear status. For example, if specimens were excluded based on microscopic examination or histological
appearance, we will score “no”. We will score “unclear” if we cannot tell.
Applicability: Are there concerns that the included patients and setting do not match the review question?
We are interested in howXpert®MTB/RIF performs in patients presumed to have extrapulmonary TBwhose specimens were evaluated
as they would be in routine practice. We will score “low concern” if Xpert® MTB/RIF was evaluated in district hospitals or primary
health clinics and “high concern” if Xpert® MTB/RIF was evaluated in central (reference) laboratories or tertiary care centres. We will
judge applicability to be of “unclear concern” if we cannot tell the level of the health system that ran the Xpert® MTB/RIF assay.
Domain 2: Index test
Risk of bias: Could the conduct or interpretation of the index test have introduced bias?
Signalling question 1: Were the index test results interpreted without knowledge of the results of the reference standard?
We will answer this question “yes” for all studies because Xpert® MTB/RIF test results are automatically generated and the user is
provided with printable test results. Thus, there is no room for subjective interpretation of test results.
Signalling question 2: If a threshold was used, was it prespecified?
As, the threshold is prespecified in all versions of Xpert® MTB/RIF, we will answer this question “yes” for all studies.
Applicability: Are there concerns that the index test, its conduct, or its interpretation differ from the review question?
We note that variations in the execution of the test might affect accuracy estimates. We will judge “low concern” if specimens were
unprocessed and the index test was performed as recommended by the manufacturer for sputum. In addition, we will also judge “low
concern” if the test was performed according to WHO standard operating procedures (WHO 2014a). We will score ’high concern’
if the test was performed in a way that deviates from these recommendations, for example, by adding a mechanical homogenization
step, because it is unclear what duration of homogenization would be sufficient and, as well, we would not be able to tell what the final
specimen input volume would be. We will score “unclear concern” if we cannot tell.
Domain 3: Reference standard
Risk of bias: Could the reference standard, its conduct, or its interpretation have introduced bias?
We will consider this domain separately for the reference standard for detection of extrapulmonary TB and the reference standard for
detection of rifampicin resistance.
Signalling question 1: Is the reference standard likely to correctly classify the target condition?
For detection of extrapulmonary TB
Culture is considered the best reference standard for TB. For the diagnosis of all forms of extrapulmonary TB (except as noted for pleural
TB below) culture is a criterion for inclusion in the review. Therefore we will score “yes” for all studies.However, there are limitations
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associated with culture; bacillary load is usually low in extrapulmonary TB leading to a reduction in the sensitivity of culture. We will
discuss this further in the Accuracy of reference standards used’ section.
For detection of pleural TB
The use of culture or a composite reference standard are criteria for inclusion in the review. We will answer this question “yes” for all
studies of pleural TB.
For detection of rifampicin resistance
Culture-based drug susceptibility testing (DST, also called conventional phenotypic method) is considered to be the best reference
standard. MTBDRplus is also a WHO-endorsed test for rifampicin resistance. We will answer this question “yes” for all studies using
culture-based DST or MTBDRplus. We will judge studies that do not use culture-based DST or MTBDRplus as “no” and judge
“unclear” if we cannot tell.
Signalling question 2: (TB) Were the reference standard results interpreted without knowledge of the results of the index test?
We will score “yes” if the reference test provides an automated result (for example, MGIT 960), blinding was explicitly stated, or it was
clear that the reference standard was performed at a separate laboratory and/or performed by different people. We will score “no” if
the study stated that the reference standard result was interpreted with knowledge of the Xpert® MTB/RIF test result. We will score
“unclear” if we cannot tell.
Signalling question 3: (Rifampicin resistance) We will add a signalling question for rifampicin resistance because judgments
might differ for TB detection and for rifampicin resistance detection, the two target conditions.
Were the reference standard results interpreted without knowledge of the results of the index test?
We will score “yes” if the reference test provided an automated result (for example, MGIT 960), blinding was explicitly stated, or it
was clear that the reference standard was performed at a separate laboratory or performed by different people, or both. We will score
“no” if the study stated that the reference standard result was interpreted with knowledge of the Xpert® MTB/RIF test result. We will
score “unclear” if we cannot tell.
Applicability: Are there concerns that the target condition as defined by the reference standard does not match the question?
We will judge “high concern” if included studies did not speciate mycobacteria isolated in culture, “low concern” if speciation was
performed, and “unclear concern” if we could not tell.
Domain 4: Flow and timing
Risk of bias: Could the patient flow have introduced bias?
Signalling question 1: Was there an appropriate interval between the index test and reference standard?
In most included studies, we expect that specimens for Xpert® MTB/RIF and culture will be obtained at the same time when patients
were evaluated for presumed TB. However, even if there were a delay of several days or weeks between index test and reference standard,
TB is a chronic disease and we consider misclassification of disease status to be unlikely, as long as treatment was not initiated in the
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interim. We will judge “yes” if the index test and reference standard were performed at the same time or if the time interval is less than
or equal to 30 days, “no” if the time interval is greater than 30 days, and “unclear” if we cannot tell.
Signalling question 2: Did all patients receive the same reference standard?
For the diagnosis of any form of extrapulmonary TB, except pleural TB, we will answer this question “yes” if all participants in the
study or a subset of participants in the study received the acceptable reference standard (solid culture, liquid culture, or both), which we
specified as a criterion for inclusion in the review. However, we acknowledge that it is possible that some specimens could undergo solid
culture and others liquid culture. This could potentially result in variations in accuracy, but we think the variation will be minimal. For
the diagnosis of pleural TB as measured against a composite reference standard, we will answer this question “yes” if all participants
received the same reference standard, “no” if not all participants received the same reference standard, and “unclear” if we cannot tell.
For rifampicin resistance detection, we will answer “yes” if all participants received the same reference standard (either culture-based
DST or MTBDRplus), “no” if not all participants received the same reference standard, and “unclear” if we cannot tell.
Signalling question 3: Were all patients included in the analysis?
We will determine the answer to this question by comparing the number of patients enrolled with the number of patients included
in the 2 x 2 tables. We will answer “yes” if the numbers matched and “no” if there were patients enrolled in the study that were not
included in the analysis. We will answer “unclear” if we cannot tell.
Judgements for overall Risk of bias’ assessments
• If we answer all signalling questions for a domain “yes” then we will judge risk of bias as “low”.
• If we answer all or most signalling questions for a domain “no”, then we will judge risk of bias as “high”.
• If we answer only one signalling question for a domain “no”, we will discuss with a third review author the “Risk of bias”
judgement.
• If we answer all or most signalling questions for a domain “unclear”, then we will judge risk of bias as “unclear”.
• If we answer only one signalling question for a domain “unclear”, we will discuss with a third review author the “Risk of bias”
judgement for the domain.
Appendix 3. Data extraction form
Data extractor MK KRS
First author
Corresponding author and email
Title of paper
Journal
Language if other than English
Year
I. Study details
Type of study: Randomized controlled trial Cross-sectional cohort (with follow-up) Case-control (exclude) Unclear/not reported
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Study data collection: Prospective Retrospective Unclear/not reported
Participant selection: Convenience Consecutive Random Other Unclear/not reported
Country:
Country income status: Low Middle High
II. Presenting signs and symptoms, setting
Presenting signs and symptoms?
Clinical setting: Inpatient Outpatient Both Unclear/Not reported
Level of laboratory running Xpert? Peripheral Intermediate Central (reference)
Comments, describe exclusions
(Tests at laboratory levels)
Peripheral: AFB (Ziehl-Neelsen, Auramine-rhodamine, Auramine-O staining) and Xpert MTB/RIF
Intermediate: Peripheral laboratory tests and culture on solid media and line probe assay (LPA) from smear positive sputum
Central: Intermediate laboratory tests and culture on liquid media and DST (1st and 2nd line anti-TB drugs) on solid or in liquid media
and LPA on positive cultures and rapid speciation tests
III. Other demographics
HIV patients included? Yes No Unclear/not reported; if yes ## and percentage? (Denominator is number tested, when possible)
Age? Median age in years (IQR); mean (SD); range Unclear/not reported
Children (< 15 years old) included: Yes No Unclear/not reported; if yes, percentage?
Percentage female included? Unclear/not reported
Past history of TB? Yes No Unclear/not reported; if yes, percentage?
Only patients who received TB treatment for ≤ 7 days were included? Yes No Unclear/not reported; if no, percentage on treatment
included?
IV. Reference standard
A. Reference standard for TB detection
Solid culture (specify): LJ 7H10 7H11 Other
Liquid culture (specify): MGIT Bactec 460 Other
Solid and liquid culture (indicate which kind above)
Were reference standard results interpreted without knowledge of index test results? Yes No Unclear/not reported
B. Composite reference standard for pleural TB
Solid culture (specify): LJ 7H10 7H11 Other
Liquid culture (specify): MGIT Bactec 460 Other
Solid and liquid culture (indicate which kind above)
Histopathology (specify): Granulomas Caseating granulomas
Were reference standard results interpreted without knowledge of index test results? Yes No Unclear/not reported
Did all patients receive the same reference standard? Yes No Unclear/not reported, if no, describe
C. Reference standard for rifampicin resistance
LJ DST MGIT DST MTBDRplus
Were reference standard results interpreted without knowledge of index test results? Yes No Unclear/not reported
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V. Sites with > five specimens (check all that apply)
A. Lymph node TB fluid tissue both fluid and tissue
B. Pleural TB fluid tissue both fluid and tissue
C. TB meningitis CSF
D. Bone and joint TB fluid tissue both fluid and tissue
E. Genitourinary TB urine other, specify
F. Peritoneal TB fluid tissue both fluid and tissue
G. Pericardial TB fluid tissue both fluid and tissue
H. Disseminated TB blood
I. Other, specify
VI. Specimen processing
Condition of specimens: fresh frozen
If frozen for > 7 days, indicate WHO not followed
For a given site, how many specimens were collected per patient? one multiple Unclear/not reported
A. Lymph node tissue, other tissue
Was the WHO standard operating procedure (SOP) followed for each specimen type?
1a. Lymph node tissue WHO followed: Yes No Unclear
1b. Lymph node tissue homogenisation step for tissue specimens: Yes No Unclear/not reported
2a. Other tissue, specify WHO followed: Yes No Unclear
2b. Other tissue homogenisation step for tissue specimens: Yes No Unclear/not reported
(For tissue, if the WHO SOP not followed, briefly describe specimen processing in comments)
WHO SOPs for specimen processing, lymph node and other tissue, sterile specimen
1. Cut the tissue specimen into small pieces in a sterile mortar.
2. Add approximately 2 mL of sterile phosphate buffered saline (PBS).
3. Grind solution of tissue and PBS until homogeneous suspension has been obtained.
4. Place approximately 0.7 mL of the homogenized tissue in a sterile, conical screw-capped tube.
5. Double volume of specimen with Xpert® Sample Reagent (1.4 mL Sample Reagent to 0.7 mL of homogenized tissue).
6. Shake tube vigorously 10 to 20 times or vortex for at least 10 seconds.
7. Incubate specimen for 10 minutes at room temperature, and again shake specimen 10-20 times or vortex for at least 10 seconds.
8. Incubate specimen at room temp. for an additional 5 minutes.
9. Transfer 2mL to Xpert® MTB/RIF cartridge
10. Load into GeneXpert and per manufacturer’s instructions
(Note: For specimens not collected in a sterile manner, the WHO SOP suggests a NaOH decontamination/concentration protocol
similar to that used for sputum)
B. CSF
3a. CSF WHO followed: Yes No Unclear
3b. CSF concentration step: Yes No Unclear/not reported
3c. CSF sample input volume specify, Unclear/not reported
(For CSF, if WHO SOP not followed, briefly describe specimen processing in comments)
WHO SOPs for CSF
If there is more than 5 mL of CSF available for testing
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1. Transfer all of the CSF specimen to a conical centrifuge tube and concentrate the specimen at 3000 x g for 15 minutes.
2. Resuspend the pellet to a final volume of 2 mL by adding Xpert® MTB/RIF Sample Reagent.
3. Transfer 2 mL of the resuspended CSF sample to the Xpert® MTB/RIF cartridge.
4. Load the cartridge into the GeneXpert instrument following the manufacturer’s instructions.
If there is 1 mL to 5 mL of CSF available
1. Add an equal volume of Sample Reagent to the CSF.
2. Mix the specimen and the Sample Reagent by vortexing as described above. After 7 to 8 minutes at room temperature, vortex the sample
as above a second time.
3. Incubate for an additional 7 to 8 minutes (15 minutes total incubation) at room temp
4. Add 2 mL of the sample mixture directly to the Xpert® MTB/RIF cartridge.
5. Load the cartridge into the GeneXpert instrument following the manufacturer’s instructions.
C. Body fluids, other then CSF
4a. Body fluid specify, processed as per manufacturer for sputum
Yes No Unclear
4b. Body fluid specify, Sample input volume specify, Unclear/not reported
5a. Body fluid specify, processed as per manufacturer for sputum (WHO followed)
Yes No Unclear
5b. Body fluid specify, sample input volume, specify, Unclear/not reported
(Add additional specimens as needed)
(For body fluids other than CSF, if manufacturer’s instructions not followed, briefly describe specimen processing in comments)
Manufacturer’s instructions for sputum
Raw specimen
1. Pour or pipette (pipette not provided) approximately 2 times the volume of the Sample Reagent into the specimen (2:1 dilution, Sample
Reagent: specimen).
2. Shake vigorously 10 to 20 times or vortex for at least 10 seconds.
3. Incubate sample for a total of 15 minutes at 20°C to 30°C.
4. Between 5 and 10 minutes into the incubation period, shake vigorously 10 to 20 times or vortex for at least 10 seconds.
Specimen sediment
Assay requires at least 0.5 mL of resuspended specimen sediment after digestion, decontamination, and concentration.
1. Use the method of Kent and Kubica and resuspend the sediment in a 67 mM phosphate/H2O buffer.
2. After resuspension, keep at least 0.5 mL of the resuspended sediment for the Xpert® MTB/RIF assay.
3. Add 1.5 mL of Sample Reagent to 0.5 mL of resuspended sediment (3:1 dilution, Sample Reagent: specimen)
4. Follow steps 2 to 4 above.
Comments on specimen processing:
VII. Results
TB detection: number error or invalid or both Xpert® MTB/RIF results over total number of cultures performed. The denominator
includes contaminated cultures and cultures that were uninterpretable.
Unclear/not reported
RIF resistance: number indeterminate Xpert results (over total number of cultures performed)
26Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Unclear/not reported
Nontuberculous mycobacteria (NTM): number of cultures with NTM (over total number of cultures performed)
Unclear/not reported
VIII. Tables
(Nontuberculous mycobacteria (NTM) should be included as not TB)
TB detection (example of table; add additional tables by site of extrapulmonary disease)
TB detection, studies on lymph node
fluid with CULTURE reference stan-
dard
Definite TB
Yes No Total
Xpert® MTB/RIF re-
sult
Positive
Negative
Total
Error/invalid
By smear status (extrapulmonary specimens)
TB detection, microscopy smear posi-
tive
Definite TB
Yes No Total
Xpert® MTB/RIF re-
sult
Positive
Negative
Total
Error/invalid
TB detection, microscopy smear nega-
tive
Definite TB
Yes No Total
Xpert® MTB/RIF re-
sult
Positive
Negative
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(Continued)
Total
Error/invalid
Rifampicin resistance detection (for all culture positive, extrapulmonary specimens)
RIF resistance detection RIF resistance
Yes No Total
Xpert® MTB/RIF re-
sult
Positive
Negative
Total
Indeterminate
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